SCHEMBL6071783

SCHEMBL6071783

CN(c1cnc[nH]1)c1cc2c(Nc3ccc(F)c(Cl)c3)c(C#N)cnc2cc1N1CCOCC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP3K8 P41279 10/20 0.57
EGFR P00533 11/20 0.55
ERBB2 P04626 8/20 0.55
MAPK13 O15264 2/20 0.53
MAPK12 P53778 2/20 0.53
MAPK11 Q15759 2/20 0.53
MAPK14 Q16539 2/20 0.53
PRKD3 O94806 1/20 0.53
PRKCG P05129 1/20 0.53
PRKCB P05771 1/20 0.53
SRC P12931 1/20 0.53
PRKCA P17252 1/20 0.53
PRKCH P24723 1/20 0.53
PRKCI P41743 1/20 0.53
PRKCE Q02156 1/20 0.53
MAP2K1 Q02750 1/20 0.53
PRKCQ Q04759 1/20 0.53
PRKCZ Q05513 1/20 0.53
PRKCD Q05655 1/20 0.53
PRKD1 Q15139 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4965565 0.92 MAP3K8 (0.53) MAP3K8EGFRERBB2MAPK13MAPK12
SCHEMBL6072168 0.89 MAP3K8 (0.52) MAP3K8EGFRERBB2MAPK13MAPK12
SCHEMBL6070981 0.88 MAP3K8 (0.73) MAP3K8EGFRERBB2MAPK13MAPK12
SCHEMBL6071772 0.82 EGFR (0.71) MAP3K8EGFRERBB2MAPK13MAPK12
SCHEMBL6072001 0.82 EGFR (0.59) MAP3K8EGFRERBB2MAPK13MAPK12
SCHEMBL6071787 0.81 MAP3K8 (0.78) MAP3K8EGFRERBB2MAPK13MAPK12
SCHEMBL4968151 0.81 EGFR (0.59) MAP3K8EGFRERBB2MAPK13MAPK12
SCHEMBL4967268 0.81 EGFR (0.59) MAP3K8EGFRERBB2MAPK13MAPK12
SCHEMBL1894502 0.81 MAP3K8 (0.65) MAP3K8EGFRERBB2MAPK13MAPK12
SCHEMBL4964899 0.79 MAP3K8 (0.54) MAP3K8EGFRERBB2MAPK13MAPK12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101223143-A 3-cyanoquinoline inhibitors of TPL2 kinase and methods of making and using the same WYETH CORP (US) 2008-07-16 CN disclosed
US-20060264460-A1 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same WYETH (US) 2006-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264460-A1 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same TNNI3K, CSNK1A1L, CDKL1 MAP3K8 84/4885EGFR 4122/4885ERBB2 1721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.